Published through 2026-11-02 17:05 UTC · Automated cloud publishing.
Court Ruling Pending on dm Eye Screening Case
Understand the event
The Landgericht Karlsruhe is expected to deliver a verdict regarding eye screenings offered at the drugstore chain dm. In an interview with FOCUS Augenoptik, Dr. Alex Hein, CEO of Skleo Health, discussed the potential legal impact of this pending ruling and outlined his company's optical partner strategy. The case centers on the legality of these screening services provided within dm stores. As of October 15, 2026, the final decision from the court remains awaited, with industry stakeholders monitoring the outcome for its implications on similar health service models in retail environments.
AI-generated from reporting · updated 18 days ago
Reporting timeline
Follow the reporting for different perspectives.
- FOCUS AugenoptikSkleo CEO Discusses Legal Impact of dm Screening Case and Optical Partner Strategy
In an interview with FOCUS Augenoptik, Skleo Health CEO Dr. Alex Hein addressed the pending court ruling regarding eye screenings offered at drugstore chain dm. The Landgericht Karlsruhe is expected to deliver its verdict in late November 2026. Hein stated that while legal clarity is necessary for modern preventive care, Skleo’s operations continue as planned. He highlighted that over 70% of Skleo users had not visited an ophthalmologist in more than two years. Regarding retail partnerships, Hein noted that most Skleo locations are within optical shops. He described a "drive-to-store" concept where customers identified by dm screenings needing correction are referred to partner opticians. Additionally, since September, health insurer mkk has covered costs for Skleo screenings targeting individuals with Type-2 diabetes, with further negotiations ongoing.